No. of patients | Percentage | |
---|---|---|
Age, years | ||
Median (range) | 53 (24–76) | |
Gender | ||
Male | 15 | 71 |
Female | 6 | 29 |
ECOG performance status | ||
0 | 4 | 19 |
1 | 16 | 76 |
2 | 1 | 5 |
Primary site | ||
Scalp | 6 | 29 |
Non-scalp | ||
Visceral organs (e.g., liver) | 7 | 33 |
Heart | 5 | 24 |
Skin | 2 | 10 |
Breast | 1 | 5 |
FNCLCC grade | ||
1 | 1 | 5 |
2 | 7 | 33 |
3 | 9 | 43 |
Unknown | 4 | 19 |
Initial stage at diagnosis | ||
III | 11 | 52 |
IV | 10 | 48 |
Laboratory (mean, SD) | ||
Hemoglobin, g/dL | 12.6 (2.0) | |
Corrected calcium, mg/dL | 9.3 (0.7) | |
Lactate dehydrogenase, U/L | 372 (243) | |
Number of metastatic site(s) | ||
Median (range) | 2 (1–4) | |
Sites of metastases | ||
Lung | 12 | 57 |
Lymph nodes | 9 | 43 |
Bone | 5 | 24 |
Spleen | 3 | 14 |
Liver | 1 | 5 |